Osseous and intestinal compartments in the humoral hypercalcemia of malignancy associated to Walker 256 tumor in rats.
The objective of the present work has been to study some aspects of bone and intestinal compartments in rats with Walker 256 carcinosarcoma, an experimental model of humoral hypercalcemia of malignancy (HHM). The results have been compared to those obtained in control animals and, also, to those obtained in Yoshida sarcoma-bearing rats, which were used as tumoral controls without hypercalcemia. Urinary hydroxyproline/creatinine ratio (OHProl/creat) is increased, in both Walker 256 and Yoshida tumor-bearing animals, showing the nonspecifity of this bone marker. However, serum tartrate-resistant acid phosphatase (TRAP) levels are increased in Walker 256 tumor-bearing animals, but they are normal in Yoshida tumor-bearing animals, indicating that TRAP is a better index of bone resorption than OHProl/creat in the HHM syndrome. The decrease of bone calcium content in Walker 256 tumor-bearing rats, not shown by Yoshida-bearing rats, also reflects an increased bone resorption due to HHM. Serum and bone osteocalcin levels are similar in control, Walker 256 and Yoshida tumor-bearing rats, but we observed a decrease in serum alkaline phosphatase levels in Walker 256 and Yoshida tumor-bearing animals, which could also be a nonspecific tumor effect, due to the presence of the neoplasia. Our results support the convenience of the employment of a nonhypercalcemic tumor group as control in the HHM study, in addition to the healthy controls. We have also observed higher 1,25-dihydroxyvitamin D serum levels in Walker 256 tumor-bearing rats than in control and Yoshida tumor-bearing rats. On the other hand, we have found normal levels in the fractional rate of intestinal calcium absorption in Walker-256 tumor-bearing rats, in spite of their high calcium levels, and a significant decrease of this parameter in Yoshida sarcoma-bearing animals. These results support the concomitant contribution of intestinal compartment to hypercalcemia, in the experimental model of HHM studied.
Torres
R
R
Unidad Metabólica, Fundación Jiménez Díaz, Madrid, Spain.
de la Piedra
C
C
Rapado
A
A
D000135:Acid Phosphatase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001825:Body Fluid Compartments; D001862:Bone Resorption / Q000378:metabolism; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002122:Calcium Chloride / Q000493:pharmacokinetics; D002132:Calcium Radioisotopes; D002296:Carcinosarcoma / Q000097:blood*; D003404:Creatinine / Q000652:urine; D004100:Dihydroxycholecalciferols / Q000097:blood; D006909:Hydroxyproline / Q000652:urine; D006934:Hypercalcemia / Q000209:etiology* / Q000378:metabolism; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D009374:Neoplasms, Experimental / Q000097:blood* / Q000150:complications; D015675:Osteocalcin / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D012517:Sarcoma, Yoshida / Q000097:blood
D002132:Calcium Radioisotopes; D004100:Dihydroxycholecalciferols; D015675:Osteocalcin; D003404:Creatinine; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D002122:Calcium Chloride; D006909:Hydroxyproline; D002118:Calcium